In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

Read on to learn why. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the ...

Franklin Resources trimmed its Pfizer stake by a smidge, selling just 25,315 shares—but when you’ve got over 16 million, ...

We put performance trends for stocks, sectors, bonds, and funds into perspective, and offer outlooks for the next quarter.

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

StoneX Group clearly didn’t skip leg day—it just bulked up its Pfizer holdings by a massive 43.5% in Q4, scooping up over ...

IDEAYA Biosciences, Inc.’s IDYA share price has surged by 10.70%, which has investors questioning if this is right time to sell.

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 13.07%, which has investors questioning if this is right time to ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...